Latigo Biotherapeutics (NASDAQ:LTGO) Reaches New 52-Week High – Should You Buy?

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) shares hit a new 52-week high on Thursday . The stock traded as high as $25.22 and last traded at $24.99, with a volume of 24875 shares. The stock had previously closed at $24.13.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th.

Latigo Biotherapeutics Stock Performance

Insider Buying and Selling at Latigo Biotherapeutics

In related news, Director James B. Tananbaum purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the purchase, the insider owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.